Objective: To investigate the effects of hormone therapy, estrogen therapy and tibolone on markers of apoptosis including bcl-2, and bax and cyclin D 1 expression in postmenopausal vaginal epithelium. Study design: Th...Objective: To investigate the effects of hormone therapy, estrogen therapy and tibolone on markers of apoptosis including bcl-2, and bax and cyclin D 1 expression in postmenopausal vaginal epithelium. Study design: Thirty postmenopausal women were randomized to the treatment protocols (0.625 mg conjugated equine estrogen (CEE) ? 2.5 mg medroxyprogesterone acetate (MPA); 2 mg estradiol valerate; 2.5 mg tibolone). After baseline vaginal biopsy, control biopsies were performed after 70 days following the initiation of the therapy. Bcl-2, bax, Bcl-2/bax ratio, cyclin D1 measurements were performed immunohistochemically. Data were analyzed by Kruskal-Wallis, Mann-Whitney U and Wilcoxon tests. Results: After the treatment period the above-mentioned parameters were not different among the groups except for cyclin D1 levels. Cyclin D1 expression was found to be strong in patients with treated estradiol valerate. Conclusions: The effects of estrogen on cyclin D1 expression were not detected with tibolone or with the addition of progesterone to estrogen in the vaginal epithelium. Cyclin D1 appeared to have stronger effects on the estrogen related proliferation compared to apoptotic markers in vaginal epithelial cells.展开更多
文摘Objective: To investigate the effects of hormone therapy, estrogen therapy and tibolone on markers of apoptosis including bcl-2, and bax and cyclin D 1 expression in postmenopausal vaginal epithelium. Study design: Thirty postmenopausal women were randomized to the treatment protocols (0.625 mg conjugated equine estrogen (CEE) ? 2.5 mg medroxyprogesterone acetate (MPA); 2 mg estradiol valerate; 2.5 mg tibolone). After baseline vaginal biopsy, control biopsies were performed after 70 days following the initiation of the therapy. Bcl-2, bax, Bcl-2/bax ratio, cyclin D1 measurements were performed immunohistochemically. Data were analyzed by Kruskal-Wallis, Mann-Whitney U and Wilcoxon tests. Results: After the treatment period the above-mentioned parameters were not different among the groups except for cyclin D1 levels. Cyclin D1 expression was found to be strong in patients with treated estradiol valerate. Conclusions: The effects of estrogen on cyclin D1 expression were not detected with tibolone or with the addition of progesterone to estrogen in the vaginal epithelium. Cyclin D1 appeared to have stronger effects on the estrogen related proliferation compared to apoptotic markers in vaginal epithelial cells.
